Conclusions

In the SENSCIS trial in subjects with SSc-ILD, the rate of decline in FVC in the placebo group was numerically greater in subjects with an extent of fibrotic ILD on HRCT ≥30% than <30% and with FVC <70% than ≥70% predicted at baseline.
Our findings suggest that nintedanib reduced the rate of decline in FVC both in subjects with extensive ILD and limited ILD at baseline.